GoodRx (GDRX) Shares Down 28% on Q4 Miss, Weak Outlook

Go back to GoodRx (GDRX) Shares Down 28% on Q4 Miss, Weak Outlook

GoodRx Holdings Inc. (GDRX) PT Lowered to $30 at Goldman Sachs

March 1, 2022 6:58 AM EST

Goldman Sachs analyst Eric Sheridan lowered the price target on GoodRx Holdings Inc. (NASDAQ: GDRX) to $30.00 (from $43.00) while maintaining a Buy rating following results.

The analyst commented, "We reiterate our Buy rating but lower our PT from $43 to $30 to reflect both lowered operating... More

GoodRx Holdings Inc. (GDRX) PT Lowered to $20 at JPMorgan

March 1, 2022 4:58 AM EST

JPMorgan analyst Doug Anmuth lowered the price target on GoodRx Holdings Inc. (NASDAQ: GDRX) to $20.00 (from $33.00) while maintaining a Underweight rating.

The analyst comments "GoodRx is focused on building the top consumer-focused digital healthcare platform in the US. Its core offering tracks... More

GoodRx Holdings, Inc. (GDRX) Misses Q4 EPS by 1c; Guides Q1 Revs Below the Street

February 28, 2022 4:13 PM EST

GoodRx Holdings, Inc. (NASDAQ: GDRX) reported Q4 EPS of $0.09, $0.01 worse than the analyst estimate of $0.10. Revenue for the quarter came in at $213.3 million versus the consensus estimate of $217.53 million.

GUIDANCE:

GoodRx Holdings, Inc. sees Q1 2022 revenue of ~$200 million, versus the... More

GoodRx Holdings, Inc. (GDRX) Announces $250M Share Buyback

February 28, 2022 4:10 PM EST

GoodRx Holdings, Inc. (Nasdaq: GDRX), a leading consumer-focused digital healthcare platform, today announced that its Board of Directors approved a share repurchase program with authorization to purchase up to $250 million of its Class A Common Stock, effective immediately.

This share repurchase program demonstrates the confidence we... More